Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.

Jimin KimSanghee ParkSeunghwan KimSeungyeon RyuHyemin HwangSua ChoYeonju HanJisu KimYusun ParkEun Kyung LeeMisu Lee

Published in: The Prostate (2024)

Our results demonstrate that ADT led to a significant upregulation in MCT1 levels. However, the combination of ENZ and SR13800 demonstrated a promising synergistic anticancer effect, highlighting a potential therapeutic significance for patients with PCa undergoing ADT.

Keyphrases

poor prognosis
cell proliferation
signaling pathway
stem cells
mesenchymal stem cells
drug delivery
replacement therapy